CNRS, UMR 7244, NBD-CSPBAT, Laboratory of Chemistry, Structures and Properties of Biomaterials and Therapeutic Agents University Paris13, Sorbonne Paris Nord, Bobigny, France.
Department of Hepatobiliary Surgery, Guangdong Provincial Key Laboratory of Regional Immunity and Diseases& Carson International Cancer Center, Shenzhen University General Hospital & Shenzhen University Clinical Medical Academy Center, Shenzhen University, Shenzhen, People's Republic of China.
Int J Nanomedicine. 2022 Sep 9;17:4105-4118. doi: 10.2147/IJN.S368458. eCollection 2022.
The realization of MRI contrast agents through chemical protocols of functionalization is a strong domain of research. In this work, we developed and formulated a novel hybrid gold nanoparticle system in which a gold salt (HAuCl) is combined with dotarem, an MRI contrast agent (DOTA) by chelation (Method IN) and stabilized by a lactose-modified chitosan polymer (CTL; Chitlac) to form DOTA IN-CTL AuNPs.
The authors demonstrate the biological efficiency of these nanoparticles in the case of three cell lines: Mia PaCa-2 (human pancreatic cancer cell line), TIB-75 (murine liver cell line) and KKU-M213 (cholangiocarcinoma cell line). DOTA IN-CTL AuNPs are stable under physiological conditions, are nontoxic, and are very efficient as PTT agents. The highlights, such as high stability and preliminary MRI in vitro and in vivo models, may be suitable for diagnosis and therapy.
We proved that DOTA IN-CTL AuNPs have several advantages: i) Biological efficacy on three cell lines: MIA PaCa-2 (human pancreatic cancer cell line), TIB-75 (murine liver cell line) and KKU-M213 (cholangiocarcinoma cell line); ii) high stability, and no-toxicity; iii) high efficiency as a PPT agent. The study conducted on MRI in vitro and in vivo models will be suitable for diagnosis and therapy.
通过功能化的化学方案实现 MRI 对比剂是一个强有力的研究领域。在这项工作中,我们开发并配制了一种新型的混合金纳米粒子系统,其中金盐(HAuCl)与 MRI 对比剂(DOTA)通过螯合(方法 IN)结合,并由乳糖修饰的壳聚糖聚合物(CTL;Chitlac)稳定,形成 DOTA IN-CTL AuNPs。
作者证明了这些纳米粒子在三种细胞系中的生物学效率:Mia PaCa-2(人胰腺癌细胞系)、TIB-75(鼠肝细胞系)和 KKU-M213(胆管癌细胞系)。DOTA IN-CTL AuNPs 在生理条件下稳定,无毒性,并且作为 PTT 剂非常有效。高稳定性和初步的 MRI 体外和体内模型等亮点可能适用于诊断和治疗。
我们证明了 DOTA IN-CTL AuNPs 具有以下几个优点:i)对三种细胞系(Mia PaCa-2(人胰腺癌细胞系)、TIB-75(鼠肝细胞系)和 KKU-M213(胆管癌细胞系))具有生物功效;ii)高稳定性和无毒性;iii)作为 PPT 剂的高效性。在体外和体内 MRI 模型上进行的研究将适用于诊断和治疗。